Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices
Concentration determinations of anticoagulants require plasma instead of whole blood, and results are not immediately available to clinicians. Monitoring anticoagulants concentration along with bedside methods may provide an alternative guide for administration of the NOAC.
The purpose of this investigation is to compare bedside coagulation assays in whole blood with plasma concentrations of the new oral anticoagulants (NOAC) in patients treated with therapeutic dosis of NOAC.
|Effect of NOAC on POCT|
|Study Design:||Observational Model: Other
Time Perspective: Retrospective
|Official Title:||Time-dependent ex Vivo Influence of Rivaroxaban on Point-of-care Devices|
|Study Start Date:||June 2012|
|Study Completion Date:||August 2013|
|Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Healthy volunteers without medication
Patients receiving Marcumar having target INR 2-3
Patients receiving therapeutic dosis of Pradaxa
Patients receiving therapeutic dosis of Xarelto